



ASX ANNOUNCEMENT

27 February 2025

## **\$4.0m Non-Dilutionary Funding**

- US-based family office provides ~A\$4.0 million in non-dilutionary funding for development of CHM CDH17 CAR-T

**Melbourne, Australia, 27 February 2025:** Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce the receipt of non-dilutionary funding.

### **US Family Office Funding ~A\$4.0 million**

Chimeric is pleased to announce that it has received US\$2.5 million (~A\$4.0 million) in non-dilutionary funding for the development of CHM CDH17 from an undisclosed US-based philanthropic family office.

Chimeric’s CEO, Dr Rebecca McQualter, said: “This is a solid confirmation of the great promise of our CHM CDH17 technology and we are very appreciative of the confidence shown.”

The funds have been received, are non-refundable and there is no further obligation on the philanthropic family office. There is no transfer of intellectual property or issue of equity to the philanthropic family office. The Company does not consider the identity of the philanthropic family office to be information that a reasonable person would expect to have a material effect on the price or value of the entity’s Company’s securities. The Company confirms that this announcement contains all material information regarding the funding and is not misleading by omission.

The corresponding CHM CDH17 Phase 1/2 trial ([www.clinicaltrials.gov](https://www.clinicaltrials.gov/ct2/show/study/NCT06055439) NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal, gastric, and intestinal neuroendocrine cancers. CHM CDH17 is a 3rd generation, novel CAR-T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastases in the most common gastrointestinal cancers.

The Phase 1 portion of this study is expected to enrol up to 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.



## **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR-T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

*Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.*

## **Contact**

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)



Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)